{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:36:51Z","timestamp":1790602611046,"version":"4.1.0"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Black pregnant patients are significantly more likely than their White counterparts to undergo peripartum urine drug screening (UDS) and subsequent reporting to child protective services (CPS).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of removing isolated cannabis use and limited prenatal care as order indications, combined with clinician-facing clinical decision support, with racial parity in peripartum UDS and CPS reporting.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This quality improvement study assessed 9396 pregnant patients at a single tertiary care center in a Midwestern US urban metropolitan region who delivered before (June 1, 2021, to September 31, 2022) and after (October 1, 2022, to January 31, 2024) the intervention.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Updated UDS indications combined with clinical decision support.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes included UDS and CPS report rate by race before vs after the intervention. The secondary outcome was the rate of nonprescribed, noncannabis substance\u2013positive UDS. Neonatal outcomes were included as balancing measures.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 9396 female patients (median [IQR] age, 29 [24-33] years; 4305 [45.8%] Black, 4277 [45.5%] White, and 814 [8.7%] other race) included in the analysis, 4639 and 4757 delivered in the preintervention and postintervention periods, respectively. There was a small but statistically significant decrease in the number of Black patients before vs after the intervention (2210 [47.6%] vs 2095 [44.0%],\n P<\/jats:italic>\n \u2009=\u2009.005); there were no significant differences in other race groups, median age, or multiparity. Before the intervention, 513 (23.2%) and 228 (11.1%) Black and White patients, respectively, had UDS (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) compared with 95 (4.5%) and 79 (3.6%) Black and White patients, respectively, after the intervention (\n P<\/jats:italic>\n \u2009=\u2009.40). Before the intervention, an association between Black race and CPS report was observed (249 [11.3%] Black and 119 [5.8%] White patients,\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001); there was no association between race and CPS report after the intervention (87 [4.2%] Black and 78 [3.5%] White patients,\n P<\/jats:italic>\n \u2009=\u2009.67). There was no association between the intervention and the percentage of UDS results that were positive for nonprescribed, noncannabis substances (107 [2.5%] preintervention vs 88 [2.0%] postintervention;\n P<\/jats:italic>\n \u2009=\u2009.14). There was no significant association between the intervention and any measured neonatal outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study, removal of isolated cannabis use and limited prenatal care as UDS indications, coupled with clinical decision support, was associated with improved racial equity in UDS testing and CPS reporting. The intervention was not associated with a significant change in UDS positivity for nonprescribed, noncannabis substances. These findings suggest that this intervention improved equity in UDS practices without decreasing identification of clinically relevant substance use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.0908","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:32:09Z","timestamp":1742211129000},"page":"e250908","source":"Crossref","is-referenced-by-count":14,"title":["Racial Equity in Urine Drug Screening Policies in Labor and Delivery"],"prefix":"10.1001","volume":"8","author":[{"given":"Vahid","family":"Azimi","sequence":"first","affiliation":[{"name":"Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Trammel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Nacke","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittaney","family":"Vaughn","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Roper","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri"},{"name":"Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Zaydman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Jackups","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim P.","family":"Schamel","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie C.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"2","key":"zoi250067r1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.siny.2019.01.007","article-title":"Screening for substance use in pregnancy and the newborn.","volume":"24","author":"Polak","year":"2019","journal-title":"Semin Fetal Neonatal Med"},{"issue":"1","key":"zoi250067r2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ogc.2022.10.015","article-title":"Opioids and opioid use disorder in pregnancy.","volume":"50","author":"Sanjanwala","year":"2023","journal-title":"Obstet Gynecol Clin North Am"},{"key":"zoi250067r3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3389\/fphar.2018.00961","article-title":"Screening pregnant women and their neonates for illicit drug use: consideration of the integrated technical, medical, ethical, legal, and social issues.","volume":"9","author":"Price","year":"2018","journal-title":"Front Pharmacol"},{"key":"zoi250067r4","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1097\/AOG.0000000000002354","article-title":"Marijuana use during pregnancy and lactation. Committee Opinion No. 722.","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"10","key":"zoi250067r6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013942","article-title":"Mandated reporters\u2019 experiences with reporting child maltreatment: a meta-synthesis of qualitative studies.","volume":"7","author":"McTavish","year":"2017","journal-title":"BMJ Open"},{"issue":"7","key":"zoi250067r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2023.100963","article-title":"Assessing the clinical utility of toxicology testing in the peripartum period.","volume":"5","author":"Siegel","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"17","key":"zoi250067r8","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1056\/NEJM199004263221706","article-title":"The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida.","volume":"322","author":"Chasnoff","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250067r9","doi-asserted-by":"publisher","first-page":"e1379","DOI":"10.1542\/peds.2008-3525","article-title":"Infant race affects application of clinical guidelines when screening for drugs of abuse in newborns.","volume":"125","author":"Ellsworth","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"zoi250067r10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/AOG.0000000000001781","article-title":"Neonatal abstinence syndrome and ethical approaches to the identification of pregnant women who use drugs.","volume":"129","author":"Terplan","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"6","key":"zoi250067r11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.acap.2023.01.012","article-title":"Disparities in maternal-infant drug testing, social work assessment, and custody at 5 hospitals.","volume":"23","author":"Cohen","year":"2023","journal-title":"Acad Pediatr"},{"issue":"4","key":"zoi250067r12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/AOG.0000000000004930","article-title":"Urine drug screening for isolated marijuana use in labor and delivery units.","volume":"140","author":"Rubin","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"10","key":"zoi250067r13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.7326\/M16-0317","article-title":"Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool for substance use screening in primary care patients.","volume":"165","author":"McNeely","year":"2016","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi250067r14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jalm\/jfab157","article-title":"Development and implementation of one-step, broad-spectrum, high-sensitivity drug screening by tandem mass spectrometry in a pediatric population.","volume":"7","author":"Tesfazghi","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"2","key":"zoi250067r15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jss.2015.09.015","article-title":"Standards for Quality Improvement Reporting Excellence 2.0: revised publication guidelines from a detailed consensus process.","volume":"200","author":"Ogrinc","year":"2016","journal-title":"J Surg Res"},{"issue":"2","key":"zoi250067r16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/AOG.0000000000004786","article-title":"Redefining child protection: addressing the harms of structural racism and punitive approaches for birthing people, dyads, and families affected by substance use.","volume":"140","author":"Wakeman","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"5","key":"zoi250067r17","first-page":"474","article-title":"A summary of maternal mortality in Missouri: a historical perspective (1999-2018).","volume":"119","author":"Carson","year":"2022","journal-title":"Mo Med"},{"issue":"2","key":"zoi250067r18","first-page":"98","article-title":"Cannabis use during pregnancy and postpartum.","volume":"66","author":"Badowski","year":"2020","journal-title":"Can Fam Physician"},{"issue":"5","key":"zoi250067r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2023.100913","article-title":"Reduction of racial disparities in urine drug testing after implementation of a standardized testing policy for pregnant patients.","volume":"5","author":"Peterson","year":"2023","journal-title":"Am J Obstet Gynecol MFM"},{"key":"zoi250067r5","unstructured":"Prenatal Drug Exposure: CAPTA Reporting Requirements for Medical Professionals. Accessed August 4, 2024. https:\/\/ifwhenhow.org\/wp-content\/uploads\/2024\/02\/2024-Prenatal-Drug-Exposure-CAPTA-Reporting-Requirements-for-Medical-Professionals.pdf"},{"key":"zoi250067r19","unstructured":"The Joint Commission. R3 Report: New Requirements to Reduce Health Care Disparities. June 20, 2022. Accessed January 28, 2025. https:\/\/www.jointcommission.org\/-\/media\/tjc\/documents\/standards\/r3-reports\/r3_disparities_july2022-6-20-2022.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831646\/azimi_2025_oi_250067_1741626321.31125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T11:32:13Z","timestamp":1742211133000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0908","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}